Navigation Links
Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
Date:9/29/2008

SEATTLE, Sept. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) will host an investor and media day in Milan, Italy on October 3, 2008. The investor day will provide an update from executive management on key strategic initiatives and regulatory milestones for the Company. Additionally, Alessandro Gianni, M.D., Director of the School of Specialization in Medical Oncology at the University of Milan, who has authored over 300 publications will be a guest speaker at the event and will provide a key perspective on the benefits of Zevalin(R) (([90Y]-ibritumomab tiuxetan) in the treatment of follicular non-Hodgkin's lymphoma. The meeting is an invitation-only event. A webcast and live teleconference of the event is available to all investors.

Webcast and Teleconference Details

Date: Friday, October 3, 2008

Time: 7:00 a.m. Eastern/1:00 p.m. Central European/4:00 a.m. Pacific Time

Conference Call Numbers

1-866-239-6425 (US Participants)

+39 02 80 20 911 (Italy)

+44 208 7929 750 (Europe)

Call-back numbers for post-listening

1-866-848-9310 (US Participants)

+39 02 80 61 3780 (Italy)

+44 207 1086 235 (Europe)

Passcode:

English: 741

Italian: 740

Live audio webcast at http://www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

E: media@ctiseattle.com

http://www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell

T: 206.272.4345

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
3. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
4. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
5. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
6. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
7. FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion
8. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
9. Synvista Therapeutics Posts Letter to Stockholders on Web Site
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 18, 2017 The global biotechnology ... 92.9 billion by 2025, according to a new ... has been adaptive of the function of outsourcing ... 2002. Among the services outsourced, clinical trial management ... Johnson & Johnson was the first pharmaceutical company ...
(Date:1/19/2017)... -- Acupath Laboratories, Inc., a leading provider of sub-specialized ... Committee that will guide the company,s vision and strategy ... , a 15-year veteran of the anatomic pathology industry, ... Chief Sales Officer .  Prior to joining Acupath ... leadership roles at several leading lab industry organizations including, ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
Breaking Biology Technology:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
Breaking Biology News(10 mins):